Actively Recruiting

Phase Not Applicable
Age: 18Years - 45Years
FEMALE
ID07009093

Utility of a Mobile Application for Young Women With Breast Cancer

Led by Wake Forest University Health Sciences · Updated on 2026-03-25

120

Participants Needed

1

Research Sites

130 weeks

Total Duration

On this page

Sponsors

W

Wake Forest University Health Sciences

Lead Sponsor

A

Atrium Health Levine Cancer Institute

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the use of mobile technology as a communication tool specifically for young women with breast cancer. This study focuses on measuring its effect on patient-reported cancer-related distress, addressing the unique challenges faced by this group. The research aims to assess the feasibility and effectiveness of a mobile application in reducing distress among women aged 18 to 45 years with breast cancer who have a certain level of distress. The study is a prospective, randomized trial with two stages. Participants will either receive access to the Mighty Pro Application, which offers social connectivity and educational resources, for 12 months or will not have access to this application. The study is conducted at a comprehensive cancer center and includes adult female patients who meet specific criteria regarding age, breast cancer diagnosis, and distress levels. Participants will be involved in the study for a total of 52 weeks, with evaluations at 26 weeks for feasibility and efficacy, and follow-up at 52 weeks to measure improvements in distress scores quantitatively. Assessments include patient-reported distress via the National Comprehensive Cancer Network Distress Thermometer and monitoring of app usage. The study monitors how well participants adhere to using the app and their distress outcomes over time, with no blinding or masking involved.

CONDITIONS

Brief Title

Utility of a Mobile Application for Young Women With Breast Cancer

Who Can Participate

Age: 18Years - 45Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Ability to understand and willingness to sign an IRB-approved informed consent
  • Age 6 18 and 45 years at the time of consent
  • Female
  • Established patient at Atrium Health Wake Forest Baptist Comprehensive Cancer Center (AHWFBCCC)
  • Histological confirmation of any type and stage (0-IV) of breast cancer
  • Screening (baseline) NCCN Distress Thermometer score 6 4
  • Access to a mobile device for trial purposes and an active email address
  • Ability to read and understand the English language. NOTE: The Mighty Pro Application is available in English only.
  • As determined by the enrolling Investigator, ability of the participant to understand and comply with study procedures for the entire length of the study
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 12 months

Participants are given access to the Mighty Pro Application to support social connectivity and education aimed at reducing cancer-related distress.

Visits may occur periodically during the 12 months to assess progress

Follow-up

Duration - Up to 52 weeks after treatment

Participants are monitored for continued efficacy of the Mighty Pro Application in improving distress scores up to one year.

Periodic visits for assessment after treatment ends

Trial Site Locations

Total: 1 location

1

Atrium Health Levine Cancer

Charlotte, North Carolina, United States, 28204

Actively Recruiting

Loading map...

Research Team

M

Maggie Dzhanumova

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Similar Trials

Investigating The Role of Key Non-coding RNA(s) in Breast Ca...

Breast Cancer

Actively Recruiting

1 location

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Bre...

Breast Cancer

Actively Recruiting

1 location

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here